East Bay Community Action Program: drugs
Schedule G of this filing lists 70 drugs, with an amount and a number of claims for each, as filed. Every amount links to its page of the filing.
The schedule's total is printed as “Total Costs of Prescription Drugs Obtained Through 340B Program Claimed for Reimbursement”. The filings describe the amounts in more than one way. Methods says more.
- 70drugs listed
- $2,101,557.87 (Schedule G, printed total, page 11 of the filing PDF)Total as filed
- 8,352 (Schedule G, printed claims total, page 11 of the filing PDF)Claims total as filed
- 6rows show “fewer than 6” for claims. What this means
All 70 drug rows
| Line | Drug | Amount as filed | Claims as filed |
|---|---|---|---|
| 1 | Invega Trinza 819 mg/2.63 mL SUSY 2.63x1 mL50458060901Listed by the FDA as Invega Trinzapaliperidone palmitate819 mg/2.63 mLinjection, suspension, extended releaseJanssen Pharmaceuticals, Inc | 154,664.97 (Schedule G, line 1, page 9 of the filing PDF) | 28 |
| 2 | Ozempic (0.25 or 0.5 mg/DOSE) 2 mg/3 mL SOPN 3x1 mL00169418113Listed by the FDA as Ozempicsemaglutide0.68 mg/mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 112,305.65 (Schedule G, line 2, page 9 of the filing PDF) | 342 |
| 3 | Invega Sustenna 234 mg/1.5 mL SUSY 1.5x1 mL50458056401Listed by the FDA as Invega Sustennapaliperidone palmitate234 mg/1.5 mLinjectionJanssen Pharmaceuticals, Inc. | 109,300.97 (Schedule G, line 3, page 9 of the filing PDF) | 84 |
| 4 | Invega Sustenna 156 mg/mL SUSY 1x1 mL50458056301Listed by the FDA as Invega Sustennapaliperidone palmitate156 mg/mLinjectionJanssen Pharmaceuticals, Inc. | 103,664.19 (Schedule G, line 4, page 9 of the filing PDF) | 120 |
| 5 | Ingrezza 60 mg CAPS 30x1 EA70370106001Listed by the FDA as Ingrezzavalbenazine60 mgcapsuleNeurocrine Biosciences, Inc. | 100,695.99 (Schedule G, line 5, page 9 of the filing PDF) | 19 |
| 6 | Invega Trinza 546 mg/1.75 mL SUSY 1.75x1 mL50458060801Listed by the FDA as Invega Trinzapaliperidone palmitate546 mg/1.75 mLinjection, suspension, extended releaseJanssen Pharmaceuticals, Inc | 99,257.53 (Schedule G, line 6, page 9 of the filing PDF) | 27 |
| 7 | Ozempic (1 mg/DOSE) 4 mg/3 mL SOPN 3x1 mL00169413013Listed by the FDA as Ozempicsemaglutide1.34 mg/mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 76,889.77 (Schedule G, line 7, page 9 of the filing PDF) | 215 |
| 8 | Abilify Maintena 400 mg PRSY 1x1 EA59148007280Listed by the FDA as Abilify MaintenaaripiprazolekitOtsuka America Pharmaceutical, Inc. | 67,409.32 (Schedule G, line 8, page 9 of the filing PDF) | 46 |
| 9 | Vraylar 3 mg CAPS 30x1 EA61874013030Listed by the FDA as Vraylarcariprazine3 mgcapsule, gelatin coatedAllergan, Inc. | 62,168.13 (Schedule G, line 9, page 9 of the filing PDF) | 78 |
| 10 | Ozempic (2 mg/DOSE) 8 mg/3 mL SOPN 3x1 mL00169477212Listed by the FDA as Ozempicsemaglutide2.68 mg/mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 61,657.77 (Schedule G, line 10, page 9 of the filing PDF) | 197 |
| 11 | Suboxone 8-2 mg FILM 30x1 EA12496120803Listed by the FDA as Suboxonebuprenorphine hydrochloride, naloxone hydrochloride8 mg; 2 mgfilm, solubleIndivior Inc. | 55,353.06 (Schedule G, line 11, page 9 of the filing PDF) | 187 |
| 12 | Vraylar 1.5 mg CAPS 30x1 EA61874011530Listed by the FDA as Vraylarcariprazine1.5 mgcapsule, gelatin coatedAllergan, Inc. | 42,279.36 (Schedule G, line 12, page 9 of the filing PDF) | 51 |
| 13 | Mounjaro 10 mg/0.5 mL SOAJ 0.5x4 mL00002147180Listed by the FDA as Mounjarotirzepatide10 mg/0.5 mLinjection, solutionEli Lilly and Company | 41,637.77 (Schedule G, line 13, page 9 of the filing PDF) | 51 |
| 14 | Aristada 882 mg/3.2 mL PRSY 3.2x1 mL65757040303Listed by the FDA as Aristadaaripiprazole lauroxil882 mg/3.2 mLinjection, suspension, extended releaseAlkermes, Inc. | 39,782.15 (Schedule G, line 14, page 9 of the filing PDF) | 19 |
| 15 | Vraylar 6 mg CAPS 30x1 EA61874016030Listed by the FDA as Vraylarcariprazine6 mgcapsule, gelatin coatedAllergan, Inc. | 39,427.62 (Schedule G, line 15, page 9 of the filing PDF) | 49 |
| 16 | Rexulti 1 mg TABS 30x1 EA59148003713Listed by the FDA as Rexultibrexpiprazole1 mgtabletOtsuka America Pharmaceutical, Inc. | 33,473.68 (Schedule G, line 16, page 9 of the filing PDF) | 44 |
| 17 | Mounjaro 7.5 mg/0.5 mL SOAJ 0.5x4 mL00002148480Listed by the FDA as Mounjarotirzepatide7.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 33,051.95 (Schedule G, line 17, page 9 of the filing PDF) | 42 |
| 18 | Mounjaro 15 mg/0.5 mL SOAJ 0.5x4 mL00002145780Listed by the FDA as Mounjarotirzepatide15 mg/0.5 mLinjection, solutionEli Lilly and Company | 30,119.19 (Schedule G, line 18, page 9 of the filing PDF) | 32 |
| 19 | Trulicity 3 mg/0.5 mL SOAJ 0.5x4 mL00002223680Listed by the FDA as Trulicitydulaglutide3 mg/0.5 mLinjection, solutionEli Lilly and Company | 29,582.27 (Schedule G, line 19, page 9 of the filing PDF) | 40 |
| 20 | Rexulti 0.5 mg TABS 30x1 EA59148003613Listed by the FDA as Rexultibrexpiprazole0.5 mgtabletOtsuka America Pharmaceutical, Inc. | 28,939.17 (Schedule G, line 20, page 10 of the filing PDF) | 36 |
| 21 | Abilify Maintena 300 mg PRSY 1x1 EA59148004580Listed by the FDA as Abilify MaintenaaripiprazolekitOtsuka America Pharmaceutical, Inc. | 28,591.07 (Schedule G, line 21, page 10 of the filing PDF) | 26 |
| 22 | Trelegy Ellipta 100-62.5-25 mcg/ACT AEPB 60x1 EA00173088710Listed by the FDA as Trelegy Elliptafluticasone furoate, umeclidinium bromide and vilanterol trifenatate100 mcg; 62.5 mcg; 25 mcgpowderGlaxoSmithKline LLC | 26,377.32 (Schedule G, line 22, page 10 of the filing PDF) | 104 |
| 23 | Rexulti 2 mg TABS 30x1 EA59148003813Listed by the FDA as Rexultibrexpiprazole2 mgtabletOtsuka America Pharmaceutical, Inc. | 23,455.82 (Schedule G, line 23, page 10 of the filing PDF) | 31 |
| 24 | Rexulti 3 mg TABS 30x1 EA59148003913Listed by the FDA as Rexultibrexpiprazole3 mgtabletOtsuka America Pharmaceutical, Inc. | 22,231.23 (Schedule G, line 24, page 10 of the filing PDF) | 31 |
| 25 | Mounjaro 5 mg/0.5 mL SOAJ 0.5x4 mL00002149580Listed by the FDA as Mounjarotirzepatide5 mg/0.5 mLinjection, solutionEli Lilly and Company | 22,038.16 (Schedule G, line 25, page 10 of the filing PDF) | 28 |
| 26 | Biktarvy tab61958250101Listed by the FDA as Biktarvybictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate50 mg; 200 mg; 25 mgtabletGilead Sciences, Inc. | 19,401.31 (Schedule G, line 26, page 10 of the filing PDF) | 7 |
| 27 | Mounjaro 12.5 mg/0.5 mL SOAJ 0.5x4 mL00002146080Listed by the FDA as Mounjarotirzepatide12.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 18,880.44 (Schedule G, line 27, page 10 of the filing PDF) | 22 |
| 28 | Mounjaro 2.5 mg/0.5 mL SOAJ 0.5x4 mL00002150680Listed by the FDA as Mounjarotirzepatide2.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 18,810.78 (Schedule G, line 28, page 10 of the filing PDF) | 24 |
| 29 | Sublocade 100 mg/0.5 mL SOSY 0.5x1 mL12496010001Listed by the FDA as Sublocadebuprenorphine100 mgsolutionIndivior Inc. | 18,139.27 (Schedule G, line 29, page 10 of the filing PDF) | 13 |
| 30 | risperiDONE Microspheres ER 50 mg SRER 1x1 EA00480145308Listed by the FDA as RisperidonekitTeva Pharmaceuticals, Inc. | 17,981.60 (Schedule G, line 30, page 10 of the filing PDF) | 28 |
| 31 | Envarsus XR tab 4 mg68992304003Listed by the FDA as Envarsus XRtacrolimus4 mgtablet, extended releaseVeloxis Pharmaceuticals, Inc | 16,244.57 (Schedule G, line 31, page 10 of the filing PDF) | 12 |
| 32 | Caplyta 42 mg CAPS 30x1 EA72060014240Listed by the FDA as Caplytalumateperone42 mgcapsuleIntra-Cellular Therapies, Inc | 14,744.38 (Schedule G, line 32, page 10 of the filing PDF) | 13 |
| 33 | Trelegy Ellipta 200-62.5-25 mcg/ACT AEPB 60x1 EA00173089310Listed by the FDA as Trelegy Elliptafluticasone furoate, umeclidinium bromide and vilanterol trifenatate200 mcg; 62.5 mcg; 25 mcgpowderGlaxoSmithKline LLC | 14,735.23 (Schedule G, line 33, page 10 of the filing PDF) | 58 |
| 34 | Wegovy 0.25 mg/0.5 mL SOAJ 0.5x4 mL00169452514Listed by the FDA as Wegovysemaglutide0.25 mg/0.5 mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 14,034.74 (Schedule G, line 34, page 10 of the filing PDF) | 24 |
| 35 | Wegovy 0.5 mg/0.5 mL SOAJ 0.5x4 mL00169450514Listed by the FDA as Wegovysemaglutide0.5 mg/0.5 mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 13,178.10 (Schedule G, line 35, page 10 of the filing PDF) | 23 |
| 36 | Descovy 200-25 mg TABS 30x1 EA61958200201Listed by the FDA as Descovyemtricitabine and tenofovir alafenamide200 mg; 25 mgtabletGilead Sciences, Inc. | 13,102.18 (Schedule G, line 36, page 10 of the filing PDF) | 13 |
| 37 | Wegovy 1.7 mg/0.75 mL SOAJ 0.75x4 mL00169451714Listed by the FDA as Wegovysemaglutide1.7 mg/0.75 mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 12,031.00 (Schedule G, line 37, page 10 of the filing PDF) | 21 |
| 38 | Xcopri tab 25 mg71699002530Listed by the FDA as Xcopricenobamate25 mgtablet, film coatedSK Life Science, Inc. | 11,937.04 (Schedule G, line 38, page 10 of the filing PDF) | 6 |
| 39 | metFORMIN HCl 625 mg TABS 30x1 EA62135068130Listed by the FDA as Metformin Hydrochloride625 mgtabletChartwell RX, LLC | 11,859.99 (Schedule G, line 39, page 10 of the filing PDF) | 11 |
| 40 | Uzedy 100 mg/0.28 mL SUSY 0.28x1 mL51759052010Listed by the FDA as Uzedyrisperidone100 mg/0.28 mLinjection, suspension, extended releaseTeva Pharmaceuticals USA, Inc. | 11,730.29 (Schedule G, line 40, page 10 of the filing PDF) | 14 |
| 41 | Aristada 441 mg/1.6 mL PRSY 1.6x1 mL65757040103Listed by the FDA as Aristadaaripiprazole lauroxil441 mg/1.6 mLinjection, suspension, extended releaseAlkermes, Inc. | 11,615.99 (Schedule G, line 41, page 10 of the filing PDF) | 11 |
| 42 | Xcopri tab 100 mg71699010030Listed by the FDA as Xcopricenobamate100 mgtablet, film coatedSK Life Science, Inc. | 11,031.46 (Schedule G, line 42, page 10 of the filing PDF) | 9 |
| 43 | Xcopri tab 50 mg71699005030Listed by the FDA as Xcopricenobamate50 mgtablet, film coatedSK Life Science, Inc. | 10,906.05 (Schedule G, line 43, page 10 of the filing PDF) | fewer than 6 (the count is not shown) |
| 44 | Uzedy 125 mg/0.35 mL SUSY 0.35x1 mL51759063010Listed by the FDA as Uzedyrisperidone125 mg/0.35 mLinjection, suspension, extended releaseTeva Pharmaceuticals USA, Inc. | 10,829.55 (Schedule G, line 44, page 10 of the filing PDF) | 10 |
| 45 | Nurtec 75 mg TBDP 8x1 EA72618300002Listed by the FDA as Nurtec ODTrimegepant sulfate75 mgtablet, orally disintegratingPfizer Laboratories Div Pfizer Inc | 10,810.14 (Schedule G, line 45, page 10 of the filing PDF) | 30 |
| 46 | Caplyta 10.5 mg CAPS 30x1 EA72060011040Listed by the FDA as Caplytalumateperone10.5 mgcapsuleIntra-Cellular Therapies, Inc | 10,532.17 (Schedule G, line 46, page 10 of the filing PDF) | 10 |
| 47 | Wegovy 1 mg/0.5 mL SOAJ 0.5x4 mL00169450114Listed by the FDA as Wegovysemaglutide1 mg/0.5 mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 10,387.62 (Schedule G, line 47, page 10 of the filing PDF) | 18 |
| 48 | RisperDAL Consta 25 mg SRER 1x1 EA50458030611Listed by the FDA as Risperdal ConstarisperidonekitJanssen Pharmaceuticals, Inc. | 10,084.38 (Schedule G, line 48, page 10 of the filing PDF) | 27 |
| 49 | Abilify Maintena 400 mg SRER 1x1 EA59148001971 | 9,197.39 (Schedule G, line 49, page 10 of the filing PDF) | 7 |
| 50 | risperiDONE Microspheres ER 25 mg SRER 1x1 EA00480123208Listed by the FDA as RisperidonekitTeva Pharmaceuticals, Inc. | 8,229.60 (Schedule G, line 50, page 10 of the filing PDF) | 26 |
| 51 | Auvelity tab 45-105 mg81968004560Listed by the FDA as Auvelitydextromethorphan hydrobromide, bupropion hydrochloride45 mg; 105 mgtablet, multilayer, extended releaseAxsome Therapeutics, Inc. | 7,620.46 (Schedule G, line 51, page 10 of the filing PDF) | 10 |
| 52 | Paxlovid new 300/100 mg T standard00069532130Listed by the FDA as Paxlovidnirmatrelvir and ritonavirkitPfizer Laboratories Div Pfizer Inc | 7,580.35 (Schedule G, line 52, page 10 of the filing PDF) | 7 |
| 53 | Vraylar 4.5 mg CAPS 30x1 EA61874014530Listed by the FDA as Vraylarcariprazine4.5 mgcapsule, gelatin coatedAllergan, Inc. | 7,414.14 (Schedule G, line 53, page 10 of the filing PDF) | 10 |
| 54 | Zepbound 7.5 mg/0.5 mL SOAJ 0.5x4 mL00002248480Listed by the FDA as Zepboundtirzepatide7.5 mg/0.5 mLinjection, solutionEli Lilly and Company | 7,366.92 (Schedule G, line 54, page 10 of the filing PDF) | 9 |
| 55 | Wegovy 2.4 mg/0.75 mL SOAJ 0.75x4 mL00169452414Listed by the FDA as Wegovysemaglutide2.4 mg/0.75 mLinjection, solutionNovo Nordisk Pharmaceutical Industries, LP | 7,354.82 (Schedule G, line 55, page 10 of the filing PDF) | 13 |
| 56 | Trintellix 20 mg TABS 30x1 EA64764075030Listed by the FDA as Trintellixvortioxetine20 mgtablet, film coatedTakeda Pharmaceuticals America, Inc. | 7,169.76 (Schedule G, line 56, page 10 of the filing PDF) | 109 |
| 57 | Entresto 24-26 mg TABS 60x1 EA00078065920Listed by the FDA as Entrestosacubitril and valsartan24 mg; 26 mgtablet, film coatedNovartis Pharmaceuticals Corporation | 7,050.32 (Schedule G, line 57, page 10 of the filing PDF) | 13 |
| 58 | Qelbree 200 mg CP24 30x1 EA17772013330Listed by the FDA as Qelbreeviloxazine hydrochloride200 mgcapsule, extended releaseSupernus Pharmaceuticals, Inc | 6,561.54 (Schedule G, line 58, page 11 of the filing PDF) | 15 |
| 59 | Abilify Maintena 400 mg SRER 1x1 EA59148024512Listed by the FDA as Abilify MaintenaaripiprazolekitOtsuka America Pharmaceutical, Inc. | 6,447.00 (Schedule G, line 59, page 11 of the filing PDF) | fewer than 6 (the count is not shown) |
| 60 | Trulicity 0.75 mg/0.5 mL SOAJ 0.5x4 mL00002143380Listed by the FDA as Trulicitydulaglutide0.75 mg/0.5 mLinjection, solutionEli Lilly and Company | 6,371.31 (Schedule G, line 60, page 11 of the filing PDF) | 15 |
| 61 | Ajovy 225 mg/1.5 mL SOAJ 1.5x1 mL51759020210Listed by the FDA as Ajovyfremanezumab-vfrm225 mg/1.5 mLinjectionTeva Pharmaceuticals USA, Inc. | 5,883.46 (Schedule G, line 61, page 11 of the filing PDF) | 31 |
| 62 | Zepbound 5 mg/0.5 mL SOAJ 0.5x4 mL00002249580Listed by the FDA as Zepboundtirzepatide5 mg/0.5 mLinjection, solutionEli Lilly and Company | 5,832.94 (Schedule G, line 62, page 11 of the filing PDF) | 7 |
| 63 | Breztri Aerosphere 160-9-4.8 mcg/ACT AERO 10.7x1 g00310461612Listed by the FDA as Breztribudesonide, glycopyrrolate, and formoterol fumarate160 mcg; 9 mcg; 4.8 mcgaerosol, meteredAstraZeneca Pharmaceuticals LP | 5,750.34 (Schedule G, line 63, page 11 of the filing PDF) | 24 |
| 64 | Incruse Ellipta 62.5 mcg/ACT AEPB 30x1 EA00173087310Listed by the FDA as Incruse Elliptaumeclidinium62.5 mcgaerosol, powderGlaxoSmithKline LLC | 5,630.74 (Schedule G, line 64, page 11 of the filing PDF) | 61 |
| 65 | Basaglar KwikPen 100 units/mL SOPN 3x5 mL00002771559Listed by the FDA as Basaglar KwikPeninsulin glargine100 IU/mLinjection, solutionEli Lilly and Company | 5,623.55 (Schedule G, line 65, page 11 of the filing PDF) | 18 |
| 66 | Ingrezza 80 mg CAPS 30x1 EA70370108001Listed by the FDA as Ingrezzavalbenazine80 mgcapsuleNeurocrine Biosciences, Inc. | 5,559.94 (Schedule G, line 66, page 11 of the filing PDF) | fewer than 6 (the count is not shown) |
| 67 | Invega Trinza 410 mg/1.32 mL SUSY 1.32x1 mL50458060701Listed by the FDA as Invega Trinzapaliperidone palmitate410 mg/1.32 mLinjection, suspension, extended releaseJanssen Pharmaceuticals, Inc | 5,540.43 (Schedule G, line 67, page 11 of the filing PDF) | fewer than 6 (the count is not shown) |
| 68 | Breo Ellipta 100-25 mcg/ACT AEPB 60x1 EA00173085910Listed by the FDA as Breo Elliptafluticasone furoate and vilanterol trifenatate100 mcg; 25 mcgpowderGlaxoSmithKline LLC | 5,452.14 (Schedule G, line 68, page 11 of the filing PDF) | 59 |
| 69 | Aristada 1,064 mg/3.9 mL PRSY 3.9x1 mL65757040403Listed by the FDA as Aristadaaripiprazole lauroxil1,064 mg/3.9 mLinjection, suspension, extended releaseAlkermes, Inc. | 5,213.76 (Schedule G, line 69, page 11 of the filing PDF) | fewer than 6 (the count is not shown) |
| 70 | Ingrezza 40 mg CAPS 30x1 EA70370204001Listed by the FDA as Ingrezzavalbenazine40 mgcapsuleNeurocrine Biosciences, Inc. | 5,060.62 (Schedule G, line 70, page 11 of the filing PDF) | fewer than 6 (the count is not shown) |
No row matches. | |||
| Total Prescription Drugs individually under $5,000 | 200,283.95 (Schedule G, row for amounts under $5,000, page 11 of the filing PDF) | 5,573 (Schedule G, claims on the row for amounts under $5,000, page 11 of the filing PDF) | |
| Total Costs of Prescription Drugs Obtained Through 340B Program Claimed for Reimbursement | 2,101,557.87 (Schedule G, printed total, page 11 of the filing PDF) | 8,352 (Schedule G, printed claims total, page 11 of the filing PDF) | |
The rows at the foot of the table are always shown. The sum above does not include them.
What “fewer than 6” means. A count of 1 to 5 is not shown on this site or in its data files. Methods, section 9, says how.
Amounts and counts are the filer’s own, in US dollars. They are written here with commas between thousands, and an amount filed with one decimal place is written with two. No value is changed: the filing and the download keep each figure as typed.
Drug names are the filer’s own words. Filers type them in many ways, so this page writes them one way: capitals, spaces, unit names such as mg and mL, a zero before a decimal point, and commas in long numbers. No word is changed, spelled out or left out, and shorthand stays as the filer typed it. The filing and the download keep each name as typed, and a search here reads both.
“Listed by the FDA as” is not part of the filing. It is the name, ingredient, strength, form and labeler that the U.S. Food and Drug Administration’s National Drug Code Directory lists for the row’s code, as downloaded on 11 November 2026. 69 of the 70 rows have one. A row has none when its code is not filed as one 11-digit code or the directory has never listed it. Where the directory has since dropped a code, the name is kept as it was last listed, and the line says so. The directory’s capitals, strengths and unit names are written one way on this page. How a code is matched
Source
- Filing PDF
- Open Schedule G on the State of Rhode Island's website
- SHA-256
- de421c0bc23d5e1126e636f34fd780ebf3980c9091cfe6fba337999a6e8f1521
- Retrieved
- 11 November 2026
- Pages used
- 9 to 11 of 13